Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gland Pharma, a Fosun Subsidiary, to Buy French CDMO for $124 Million

publication date: Nov 30, 2022

India’s Gland Pharma, a majority owned CDMO subsidiary of Fosun Pharma, will expand its geographical footprint by paying $124 million to acquire France’s Cenexi Group. Both companies focus on CDMO services for injectable products. Founded in 2004, Cenexi offers CDMO services with expertise in sterile liquid and lyophilized fill-finished drugs, including oncology and complex products. In 2017, Fosun paid $1.1 billion for a 74% stake in Gland. Now, Fosun owns 58% of Gland, which has a market cap of $3.8 billion. More details....

Stock Symbols: (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China